Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-CHALLENGE
2024-511076-32-00Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hypercholesterolemia and atherosclerotic disease comparing Inclisiran arm with Bempedoic acid arm (2 arms). Started May 2024; status: completed.
02
Drugs
inclisiranbempedoic acid
03
Conditions
hypercholesterolemiaatherosclerotic disease
Beyond the preview
Go deeper on 2024-511076-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511076-32-00.